Vivo Capital LLC lowered its position in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 15.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,610,177 shares of the company's stock after selling 639,741 shares during the quarter. Verona Pharma accounts for approximately 4.6% of Vivo Capital LLC's holdings, making the stock its 6th biggest holding. Vivo Capital LLC owned about 4.47% of Verona Pharma worth $58,088,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Verona Pharma by 71.4% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 67,365 shares of the company's stock valued at $1,084,000 after buying an additional 28,071 shares during the last quarter. Eventide Asset Management LLC boosted its stake in Verona Pharma by 62.1% during the 4th quarter. Eventide Asset Management LLC now owns 1,377,781 shares of the company's stock valued at $27,390,000 after acquiring an additional 527,781 shares during the last quarter. Parkman Healthcare Partners LLC grew its holdings in Verona Pharma by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 504,742 shares of the company's stock worth $10,034,000 after acquiring an additional 86,809 shares in the last quarter. Superstring Capital Management LP bought a new stake in shares of Verona Pharma in the 4th quarter worth about $2,466,000. Finally, Artia Global Partners LP acquired a new stake in shares of Verona Pharma in the 4th quarter valued at about $2,600,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several analysts recently weighed in on VRNA shares. Piper Sandler boosted their price objective on Verona Pharma from $31.00 to $36.00 and gave the company an "overweight" rating in a report on Tuesday, April 16th. Wedbush restated an "outperform" rating and set a $33.00 price objective on shares of Verona Pharma in a research note on Friday, March 1st. Finally, HC Wainwright reiterated a "buy" rating and set a $32.00 target price on shares of Verona Pharma in a research note on Monday, March 4th. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat, Verona Pharma presently has an average rating of "Buy" and an average price target of $33.60.
View Our Latest Analysis on Verona Pharma
Verona Pharma Stock Performance
NASDAQ VRNA traded up $0.16 during trading hours on Friday, hitting $15.47. The company had a trading volume of 260,511 shares, compared to its average volume of 413,627. Verona Pharma plc has a fifty-two week low of $11.83 and a fifty-two week high of $23.81. The firm has a market cap of $1.25 billion, a P/E ratio of -22.42 and a beta of 0.40. The company has a quick ratio of 33.33, a current ratio of 33.33 and a debt-to-equity ratio of 0.20. The business has a fifty day simple moving average of $16.34 and a 200-day simple moving average of $16.11.
Verona Pharma (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.07. Equities analysts predict that Verona Pharma plc will post -1.32 EPS for the current year.
About Verona Pharma
(
Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Featured Articles
Want to see what other hedge funds are holding VRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verona Pharma plc (NASDAQ:VRNA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Verona Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.
While Verona Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
